SCHEMBL7218151

SCHEMBL7218151

CCCOCCOc1ccccc1COc1ccc2c(c1)C=C(C(=O)OC)CCS2(=O)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.34
PARP14 Q460N5 1/20 0.34
PARP10 Q53GL7 1/20 0.34
MAPT P10636 3/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
TDP1 Q9NUW8 3/20 0.33
LMNA P02545 2/20 0.33
HSP90AA1 P07900 1/20 0.32
HSP90B1 P14625 1/20 0.32
SPHK2 Q9NRA0 2/20 0.32
SPHK1 Q9NYA1 2/20 0.32
ALDH1A1 P00352 6/20 0.32
KDM4E B2RXH2 5/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
HPGD P15428 4/20 0.32
GAA P10253 3/20 0.32
TP53 P04637 2/20 0.32
TSHR P16473 2/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7218226 0.94 PARP14 (0.34) PPARDPARP14PARP10MAPTL3MBTL1
SCHEMBL7216783 0.91 PPARD (0.35) PPARDPARP14PARP10MAPTL3MBTL1
SCHEMBL7218091 0.89 PARP10 (0.37) PARP14PARP10MAPTL3MBTL1TDP1
SCHEMBL7218062 0.88 MTNR1B (0.32) PPARDHSD17B10NPSR1
SCHEMBL7216128 0.88 PARP10 (0.44) PARP14PARP10MAPTL3MBTL1SPHK2
SCHEMBL7218123 0.86 PPARD (0.43) PPARDMAPTL3MBTL1TDP1HSP90AA1
SCHEMBL7215817 0.86 NPC1 (0.38) PPARDMAPTL3MBTL1LMNAHSP90AA1
SCHEMBL7215840 0.86 PPARD (0.37) PPARDPARP14PARP10L3MBTL1KDM4E
SCHEMBL7218231 0.85 MAPT (0.34) PPARDPARP14PARP10MAPTL3MBTL1
SCHEMBL7218076 0.84 S1PR1 (0.36) PPARDMAPTLMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed